Greenville

Az itteni vizsgálatok

Miről szól a helyszín 43 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Asztma9 vizsgálat
• Krónikus vesebetegség9 vizsgálat
• Magas vérnyomás5 vizsgálat
• Áttétes emlőrák4 vizsgálat
• Amiloidózis3 vizsgálat
• Krónikus obstruktív tüdőbetegség (COPD)3 vizsgálat
• Tüdőrák3 vizsgálat
• Follikuláris limfóma2 vizsgálat
• Köpenysejtes limfóma2 vizsgálat
• Prosztatarák2 vizsgálat
• Szívelégtelenség2 vizsgálat
• 2-es típusú cukorbetegség1 vizsgálat
• és még 9

Fázis

• 3. fázis26 vizsgálat
• 2. fázis6 vizsgálat
• 4. fázis4 vizsgálat
• 1/2. fázis2 vizsgálat
• 1. fázis1 vizsgálat

Állapot

• Lezárult16 vizsgálat
• Fut, nem toboroz10 vizsgálat
• Toboroz9 vizsgálat
• Még nem toboroz5 vizsgálat
• Leállították2 vizsgálat
• Visszavonták1 vizsgálat

Fő szponzor

• AstraZeneca37 vizsgálat
• Acerta Pharma BV3 vizsgálat
• Alexion Pharmaceuticals, Inc.2 vizsgálat
• Maze Therapeutics1 vizsgálat

Futó vizsgálatok

• Még nem toboroz

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Toboroz

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· 3. fázis· AstraZeneca· Forrás

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

  NCT07222917· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

  NCT06830629· 2. fázis· Maze Therapeutics· Forrás

  Contact: Maze Therapeutics

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· AstraZeneca· Forrás

• Fut, nem toboroz

  Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care

  NCT06422689· 4. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Fut, nem toboroz

  Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

  NCT06087835· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT05348577· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

  NCT04862663· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

  NCT02972840· 3. fázis· Acerta Pharma BV· Forrás

• Fut, nem toboroz

  Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

  NCT02180711· 1/2. fázis· Acerta Pharma BV· Forrás

• Fut, nem toboroz

  Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

  NCT00099437· 3. fázis· AstraZeneca· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus vesebetegség4 toboroz
• Amiloidózis2 toboroz
• Tüdőrák2 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Asztma1 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)1 toboroz
• Magas vérnyomás1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhtestrák1 toboroz
• Prosztatarák1 toboroz
• Szívelégtelenség1 toboroz

Lezárt vizsgálatok

• Lezárult

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· 3. fázis· AstraZeneca· Forrás

• Toboroz

  An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  NCT05835310· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

  NCT06168409· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

  NCT06067828· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

  NCT05967806· AstraZeneca· Forrás

• Leállították

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· AstraZeneca· Forrás

• Lezárult

  Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

  NCT05329194· 4. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

  NCT05432167· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· 2. fázis· AstraZeneca· Forrás

• Leállították

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· 4. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· 4. fázis· AstraZeneca· Forrás

• Lezárult

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Forrás

• Lezárult

  ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

  NCT02362035· 1/2. fázis· Acerta Pharma BV· Forrás

• Lezárult

  AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

  NCT01597388· 1. fázis· AstraZeneca· Forrás